# | Title | Journal | Year | Citations |
---|
1 | The measurement of disability | International Clinical Psychopharmacology | 1996 | 1,159 |
2 | Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs) | International Clinical Psychopharmacology | 1994 | 418 |
3 | Depression in the community | International Clinical Psychopharmacology | 1997 | 413 |
4 | Anxiety and the Anxiety Disorders | International Clinical Psychopharmacology | 1990 | 396 |
5 | A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder | International Clinical Psychopharmacology | 2012 | 375 |
6 | Efficacy of treatments for anxiety disorders | International Clinical Psychopharmacology | 2015 | 369 |
7 | Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study | International Clinical Psychopharmacology | 2002 | 323 |
8 | A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500) | International Clinical Psychopharmacology | 2002 | 322 |
9 | Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale | International Clinical Psychopharmacology | 2008 | 319 |
10 | Antioxidant enzyme activities and oxidative stress in affective disorders | International Clinical Psychopharmacology | 2004 | 301 |
11 | The social and economic burden of treatment-resistant schizophrenia | International Clinical Psychopharmacology | 2014 | 289 |
12 | Biological rhythm disturbances in mood disorders | International Clinical Psychopharmacology | 2006 | 279 |
13 | Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial | International Clinical Psychopharmacology | 2007 | 268 |
14 | Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale | International Clinical Psychopharmacology | 1995 | 263 |
15 | Imputing response rates from means and standard deviations in meta-analyses | International Clinical Psychopharmacology | 2005 | 261 |
16 | A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia | International Clinical Psychopharmacology | 1994 | 256 |
17 | Effect of a Serotonin and Noradrenaline Uptake Inhibitor in Panic Disorder; a Double-blind Comparative Study with Fluvoxamine and Maprotiline | International Clinical Psychopharmacology | 1988 | 242 |
18 | A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables | International Clinical Psychopharmacology | 1995 | 242 |
19 | Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey | International Clinical Psychopharmacology | 2000 | 234 |
20 | The GRID-HAMD: standardization of the Hamilton Depression Rating Scale | International Clinical Psychopharmacology | 2008 | 232 |
21 | Pharmacology and pharmacokinetics of milnacipran | International Clinical Psychopharmacology | 2002 | 228 |
22 | Selective serotonin reuptake inhibitors | International Clinical Psychopharmacology | 1994 | 227 |
23 | Depot neuroleptics in relapse prevention | International Clinical Psychopharmacology | 1995 | 217 |
24 | Sexual problems in healthy and depressed persons | International Clinical Psychopharmacology | 1998 | 217 |
25 | Equivalence of St Johnʼs wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mildmoderate depression | International Clinical Psychopharmacology | 2000 | 210 |
26 | A Comparison of Fluoxetine Imipramine and Placebo in Patients with Bipolar Depressive Disorder | International Clinical Psychopharmacology | 1989 | 208 |
27 | A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder | International Clinical Psychopharmacology | 2008 | 205 |
28 | Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study | International Clinical Psychopharmacology | 2006 | 199 |
29 | A comparative review of escitalopram, paroxetine, and sertraline | International Clinical Psychopharmacology | 2014 | 198 |
30 | Impulsive aggression and central serotonergic system function in humans | International Clinical Psychopharmacology | 1992 | 197 |
31 | Escitalopram 10???mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care | International Clinical Psychopharmacology | 2002 | 197 |
32 | Predictors of an acute antidepressant response to fluoxetine and sertraline | International Clinical Psychopharmacology | 1999 | 196 |
33 | Trihexyphenidyl (Artane) abuse in schizophrenic patients | International Clinical Psychopharmacology | 1996 | 191 |
34 | SPRINT: a brief global assessment of post-traumatic stress disorder | International Clinical Psychopharmacology | 2001 | 186 |
35 | The neuropharmacology of serotonin and noradrenaline in depression | International Clinical Psychopharmacology | 2002 | 185 |
36 | Tolerability of paliperidone: a meta-analysis of randomized, controlled trials | International Clinical Psychopharmacology | 2010 | 184 |
37 | Guideline for the Dosage of Neuroleptics. I | International Clinical Psychopharmacology | 1989 | 181 |
38 | D-cycloserine does not enhance exposure–response prevention therapy in obsessive–compulsive disorder | International Clinical Psychopharmacology | 2007 | 179 |
39 | Dose correspondence between olanzapine long-acting injection and oral olanzapine | International Clinical Psychopharmacology | 2011 | 178 |
40 | Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer??s disease | International Clinical Psychopharmacology | 2003 | 177 |
41 | The mesolimbic dopamine system as a target for rapid antidepressant action | International Clinical Psychopharmacology | 1997 | 175 |
42 | The use of lorazepam TID for chronic insomnia | International Clinical Psychopharmacology | 1999 | 175 |
43 | The effects of D- and L-fenfluramine (and their interactions with D-amphetamine) on psychomotor function and mood | International Clinical Psychopharmacology | 1996 | 174 |
44 | Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study | International Clinical Psychopharmacology | 2004 | 174 |
45 | The role of serotonin in depression and anxiety | International Clinical Psychopharmacology | 1995 | 172 |
46 | The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission | International Clinical Psychopharmacology | 1995 | 170 |
47 | Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder | International Clinical Psychopharmacology | 2019 | 170 |
48 | Safety of mirtazapine: a review | International Clinical Psychopharmacology | 1995 | 169 |
49 | Clinical utility of milnacipran in comparison with other antidepressants | International Clinical Psychopharmacology | 2002 | 169 |
50 | Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks | International Clinical Psychopharmacology | 1995 | 168 |